Introduction:

Around the world, the Medical Community concerned with blood transfusions being recommended more than it is indicated. Allogenic blood transfusions have been erroneously considered as a safe procedure with unquestionable benefits; as well as it is not completely safe for cancer anemia treatment.

Objective:

To analyse the use of blood components at the Oncological Hospital Marie Curie of Camagüey

Method:

Longitudinal, descriptive study, retrospectively sustained in the analysis of the consumption of blood components at the hospital from January 2018 to December 2021. Analysed variables were the monthly quantity of transfused units, cellular and plasma, blood products, total of admitted patients, total transfused patients and haemotherapy rate for each 1000 patients admitted at the hospital.

Results:

Red blood cells were the most requested components during the study period. From 2018 to 2021 (except three months). Haemotherapy rate stayed above 245 blood component transfused by each 1000 admitted patients.

Conclusions:

According to compliance with the haemotherapy rate, the use of blood components was evaluated unfavorably in analyzed period. With the indispensable application of the clinical method, education in transfusion medical practice, the consensus criteria as a guide for anemia cancer treatment, and patient-centered attention (personalized treatments), will improve the patient's safety and the quality of the medical treatment.

        · |     · |     · ( pdf )